InfuSystem (INFU) 10-Q 9 Aug 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2023	Aug. 06, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-35020
Entity Registrant Name	INFUSYSTEM HOLDINGS, INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-3341405
Entity Address, Address Line One	3851 West Hamlin Road
Entity Address, City or Town	Rochester Hills
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48309
City Area Code	248
Local Phone Number	291-1210
Title of Each Class	Common Stock, par value $0.0001 per share
Trading Symbol(s)	INFU
Name of Each Exchange on which Registered	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		21,054,756
Entity Central Index Key	0001337013
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 134	$ 165
Accounts receivable, net	18,870	16,871
Inventories	5,706	4,821
Other current assets	3,916	2,922
Total current assets	28,626	24,779
Medical equipment for sale or rental	3,206	2,790
Medical equipment in rental service, net of accumulated depreciation	37,697	39,450
Property & equipment, net of accumulated depreciation	4,303	4,385
Goodwill	3,710	3,710
Intangible assets, net	7,942	8,436
Operating lease right of use assets	4,392	4,168
Deferred income taxes	9,739	9,625
Derivative financial instruments	1,910	1,965
Other assets	1,224	80
Total assets	102,749	99,388
Current liabilities:
Accounts payable	5,481	8,341
Current portion of long-term debt	0	0
Other current liabilities	7,386	6,126
Total current liabilities	12,867	14,467
Long-term debt, net of current portion	36,140	33,157
Operating lease liabilities, net of current portion	3,786	3,761
Total liabilities	52,793	51,385
Stockholders’ equity:
Preferred stock, $0.0001 par value: authorized 1,000,000 shares; none issued	0	0
Common stock, $0.0001 par value: authorized 200,000,000 shares; 21,051,045 shares issued and outstanding as of June 30, 2023 and 20,781,977 shares issued and outstanding as of December 31, 2022	2	2
Additional paid-in capital	107,898	105,856
Accumulated other comprehensive income	1,442	1,489
Retained deficit	(59,386)	(59,344)
Total stockholders’ equity	49,956	48,003
Total liabilities and stockholders’ equity	$ 102,749	$ 99,388

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized (in shares)	1,000,000	1,000,000
Preferred stock, issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock,, authorized (in shares)	200,000,000	200,000,000
Common stock, issued (in shares)	21,051,045	20,781,977
Common stock, outstanding (in shares)	21,051,045	20,781,977

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Net revenues	$ 31,735	$ 27,042	$ 62,105	$ 53,805
Cost of revenues	15,293	12,141	30,123	23,537
Gross profit	16,442	14,901	31,982	30,268
Selling, general and administrative expenses:
Provision for doubtful accounts	(67)	(41)	47	6
Amortization of intangibles	247	711	495	1,421
Selling and marketing	2,985	3,083	6,209	6,402
General and administrative	12,029	10,941	24,090	22,757
Total selling, general and administrative	15,194	14,694	30,841	30,586
Operating income (loss)	1,248	207	1,141	(318)
Other income (expense):
Interest expense	(620)	(314)	(1,104)	(591)
Other income (expense)	2	(30)	(33)	(58)
Income (loss) before income taxes	630	(137)	4	(967)
(Provision for) benefit from income taxes	(195)	(27)	107	435
Net income (loss)	$ 435	$ (164)	$ 111	$ (532)
Net income (loss) per share:
Basic (in dollars per share)	$ 0.02	$ (0.01)	$ 0.01	$ (0.03)
Diluted (in dollars per share)	$ 0.02	$ (0.01)	$ 0.01	$ (0.03)
Weighted average shares outstanding:
Basic (in shares)	20,955,048	20,583,928	20,904,315	20,596,580
Diluted (in shares)	21,600,346	20,583,928	21,565,667	20,596,580
Comprehensive income:
Net income (loss)	$ 435	$ (164)	$ 111	$ (532)
Other comprehensive income (loss):
Unrealized gain (loss) on hedges	228	244	(54)	1,149
(Provision for) benefit from income tax on unrealized hedge gain (loss)	(56)	(59)	7	(277)
Net comprehensive income	$ 607	$ 21	$ 64	$ 340

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid in Capital	Retained Deficit	Accumulated Other Comprehensive Income	Treasury Stock
Beginning balance (in shares) at Dec. 31, 2021		20,700,000
Beginning balance at Dec. 31, 2021	$ 48,272	$ 2	$ 101,905	$ (53,903)	$ 268	$ 0
Beginning balance (in shares) at Dec. 31, 2021						0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based shares issued upon vesting - gross (in shares)		388,000
Stock-based shares issued upon vesting - gross	473		473
Stock-based compensation expense	2,170		2,170
Employee stock purchase plan (in shares)		28,000
Employee stock purchase plan	236		236
Common stock repurchased as part of share repurchase program (in shares)		(349,000)
Common stock repurchased as part of share repurchase program	(4,356)			(4,356)
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation (in shares)		(72,000)
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation	(638)		(638)
Other comprehensive income (loss)	872				872
Net income (loss)	(532)			(532)
Ending balance (in shares) at Jun. 30, 2022		20,695,000
Ending balance at Jun. 30, 2022	46,497	$ 2	104,146	(58,791)	1,140	$ 0
Ending balance (in shares) at Jun. 30, 2022						0
Beginning balance (in shares) at Mar. 31, 2022		20,540,000
Beginning balance at Mar. 31, 2022	46,053	$ 2	103,373	(58,277)	955	$ 0
Beginning balance (in shares) at Mar. 31, 2022						0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based shares issued upon vesting - gross (in shares)		263,000
Stock-based shares issued upon vesting - gross	234		234
Stock-based compensation expense	1,123		1,123
Common stock repurchased as part of share repurchase program (in shares)		(39,000)
Common stock repurchased as part of share repurchase program	(350)			(350)
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation (in shares)		(69,000)
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation	(584)		(584)
Other comprehensive income (loss)	185				185
Net income (loss)	(164)			(164)
Ending balance (in shares) at Jun. 30, 2022		20,695,000
Ending balance at Jun. 30, 2022	$ 46,497	$ 2	104,146	(58,791)	1,140	$ 0
Ending balance (in shares) at Jun. 30, 2022						0
Beginning balance (in shares) at Dec. 31, 2022	20,781,977	20,782,000
Beginning balance at Dec. 31, 2022	$ 48,003	$ 2	105,856	(59,344)	1,489	$ 0
Beginning balance (in shares) at Dec. 31, 2022						0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based shares issued upon vesting - gross (in shares)		309,000
Stock-based shares issued upon vesting - gross	586		586
Stock-based compensation expense	1,736		1,736
Employee stock purchase plan (in shares)		41,000
Employee stock purchase plan	243		243
Common stock repurchased as part of share repurchase program (in shares)		(22,000)
Common stock repurchased as part of share repurchase program	(153)			(153)
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation (in shares)		(59,000)
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation	(523)		(523)
Other comprehensive income (loss)	(47)				(47)
Net income (loss)	$ 111			111
Ending balance (in shares) at Jun. 30, 2023	21,051,045	21,051,000
Ending balance at Jun. 30, 2023	$ 49,956	$ 2	107,898	(59,386)	1,442	$ 0
Ending balance (in shares) at Jun. 30, 2023						0
Beginning balance (in shares) at Mar. 31, 2023		20,931,000
Beginning balance at Mar. 31, 2023	48,261	$ 2	106,810	(59,821)	1,270	$ 0
Beginning balance (in shares) at Mar. 31, 2023						0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based shares issued upon vesting - gross (in shares)		142,000
Stock-based shares issued upon vesting - gross	271		271
Stock-based compensation expense	1,016		1,016
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation (in shares)		(22,000)
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation	(199)		(199)
Other comprehensive income (loss)	172				172
Net income (loss)	$ 435			435
Ending balance (in shares) at Jun. 30, 2023	21,051,045	21,051,000
Ending balance at Jun. 30, 2023	$ 49,956	$ 2	$ 107,898	$ (59,386)	$ 1,442	$ 0
Ending balance (in shares) at Jun. 30, 2023						0

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
OPERATING ACTIVITIES
Net income (loss)	$ 111	$ (532)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Provision for doubtful accounts	47	6
Depreciation	5,801	5,395
Loss on disposal of and reserve adjustments for medical equipment	828	1,101
Gain on sale of medical equipment	(1,402)	(883)
Amortization of intangible assets	495	1,421
Amortization of deferred debt issuance costs	78	37
Stock-based compensation	1,736	2,170
Deferred income taxes	(106)	(435)
Changes in assets - (increase)/decrease:
Accounts receivable	(506)	(924)
Inventories	(885)	(937)
Other current assets	(994)	599
Other assets	(1,719)	(19)
Changes in liabilities - (decrease)/increase:
Accounts payable and other liabilities	(1,183)	2,496
NET CASH PROVIDED BY OPERATING ACTIVITIES	2,301	9,495
INVESTING ACTIVITIES
Purchase of medical equipment	(6,994)	(6,669)
Purchase of property and equipment	(494)	(336)
Proceeds from sale of medical equipment, property and equipment	2,098	2,081
NET CASH USED IN INVESTING ACTIVITIES	(5,390)	(4,924)
FINANCING ACTIVITIES
Principal payments on long-term debt	(29,451)	(20,665)
Cash proceeds from long-term debt	32,585	21,218
Debt issuance costs	(229)	0
Cash payment of contingent consideration	0	(750)
Common stock repurchased as part of share repurchase program	(153)	(4,356)
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans	(523)	(639)
Cash proceeds from stock plans	829	746
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	3,058	(4,446)
Net change in cash and cash equivalents	(31)	125
Cash and cash equivalents, beginning of period	165	186
Cash and cash equivalents, end of period	$ 134	$ 311

Basis of Presentation, Nature o

Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies	Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies The terms “InfuSystem”, the “Company”, “we”, “our” and “us” are used herein to refer to InfuSystem Holdings, Inc. and its subsidiaries. InfuSystem is a leading provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care. The Company provides products and services to hospitals, oncology practices and facilities and other alternative site health care providers. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada. The Company operates in two reportable segments, Patient Services and Device Solutions. During the second quarter of 2023, the Company renamed its two operating segments. Prior to that time the Patient Services segment was known as Integrated Therapy Services and the Device Solutions segment was known as Durable Medical Equipment Services. The changes were for marketing purposes only and there were no changes to the operations of either segment. The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The accompanying unaudited condensed consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state the Company’s results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC on March 16, 2023. The unaudited condensed consolidated financial statements are prepared in conformity with GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods.

Recent Accounting Pronouncement

Recent Accounting Pronouncements and Developments	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Recent Accounting Pronouncements and Developments	Recent Accounting Pronouncements and DevelopmentsIn June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-13, “Financial Instruments (Topic 326) Credit Losses”. Topic 326 changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. The Company's adoption of this standard on January 1, 2023 did not have a material effect on its consolidated balance sheets, statements of operations, statements of cash flows or related disclosures.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition The following tables present the Company’s disaggregated revenue by offering type (in thousands): Three Months Ended 2023 2022 Total Net Revenues Percentage of Total Net Revenues Total Net Revenues Percentage of Total Net Revenues Patient Services Third-Party Payer Rentals $ 14,634 46.1 % $ 13,896 51.4 % Device Solutions Direct Payer Rentals 4,591 14.4 % 4,640 17.1 % Patient Services Direct Payer Rentals 3,356 10.6 % 3,342 12.4 % Device Solutions Product Sales 3,864 12.2 % 3,655 13.5 % Device Solutions - Service 3,961 12.5 % 1,502 5.6 % Patient Services Product Sales 1,329 4.2 % 7 — % Total $ 31,735 100.0 % $ 27,042 100.0 % Six Months Ended 2023 2022 Total Net Revenues Percentage of Total Net Revenues Total Net Revenues Percentage of Total Net Revenues Patient Services Third-Party Payer Rentals $ 29,442 47.4 % $ 27,264 50.7 % Device Solutions Direct Payer Rentals 9,098 14.7 % 9,415 17.5 % Patient Services Direct Payer Rentals 6,828 11.0 % 6,529 12.1 % Device Solutions Product Sales 7,603 12.2 % 7,313 13.6 % Device Solutions - Service 7,311 11.8 % 3,191 5.9 % Patient Services Product Sales 1,823 2.9 % 93 0.2 % Total $ 62,105 100.0 % $ 53,805 100.0 %

Medical Equipment

Medical Equipment	6 Months Ended
	Jun. 30, 2023
Medical Equipment [Abstract]
Medical Equipment	Medical Equipment Medical equipment consisted of the following (in thousands): June 30, December 31, 2022 Medical equipment for sale or rental $ 3,239 $ 2,802 Medical equipment for sale or rental - pump reserve (33) (12) Medical equipment for sale or rental - net 3,206 2,790 Medical equipment in rental service 101,165 99,163 Medical equipment in rental service - pump reserve (2,699) (2,270) Accumulated depreciation (60,769) (57,443) Medical equipment in rental service - net 37,697 39,450 Total $ 40,903 $ 42,240 Depreciation expense for medical equipment for the three and six months ended June 30, 2023 was $2.6 million and $5.3 million, respectively, compared to $2.5 million and $4.9 million for the same prior year periods, respectively. This expense was recorded in “cost of revenues” for each period. The pump reserve for medical equipment in rental service represents an estimate for medical equipment that is considered to be missing. The reserve calculated is equal to the net book value of assets that have not returned from the field within a certain timeframe.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consisted of the following (in thousands): June 30, 2023 December 31, 2022 Gross Assets Accumulated Depreciation Total Gross Assets Accumulated Depreciation Total Furniture, fixtures, and equipment $ 6,162 $ (3,600) $ 2,562 $ 5,710 $ (3,252) $ 2,458 Automobiles 87 (85) 2 87 (83) 4 Leasehold improvements 3,498 (1,759) 1,739 3,498 (1,575) 1,923 Total $ 9,747 $ (5,444) $ 4,303 $ 9,295 $ (4,910) $ 4,385 Depreciation expense for property and equipment for both the three and six months ended June 30, 2023 and 2022 was $0.2 million and $0.5 million, respectively. This expense was recorded in “general and administrative expenses” for each period.

Goodwill & Intangible Assets

Goodwill & Intangible Assets	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill & Intangible Assets	Goodwill & Intangible Assets The changes in the carrying value of goodwill by segment for the six months ended June 30, 2023 are as follows (in thousands): Device Solutions (a) Balance as of December 31, 2022 $ 3,710 Goodwill acquired — Balance as of June 30, 2023 $ 3,710 (a) The Patient Services segment had no recorded goodwill during the reported periods. The carrying amount and accumulated amortization of intangible assets consisted of the following (in thousands): June 30, 2023 December 31, 2022 Gross Assets Accumulated Amortization Net Gross Assets Accumulated Amortization Net Nonamortizable intangible assets Trade names $ 2,000 $ — $ 2,000 $ 2,000 $ — $ 2,000 Amortizable intangible assets: Trade names 23 (23) — 23 (23) — Physician and customer relationships 38,834 (33,944) 4,890 38,834 (33,594) 5,240 Non-competition agreements 472 (208) 264 472 (161) 311 Unpatented technology 943 (325) 618 943 (258) 685 Software 10,300 (10,130) 170 10,300 (10,100) 200 Total nonamortizable and amortizable intangible assets $ 52,572 $ (44,630) $ 7,942 $ 52,572 $ (44,136) $ 8,436 Amortization expense for the three and six months ended June 30, 2023 was $0.2 million and $0.5 million, respectively, compared to $0.7 million and $1.4 million, respectively, for the same prior year periods. This expense was recorded in “amortization of intangibles expenses” for each period. Expected remaining annual amortization expense for the next five years for intangible assets recorded as of June 30, 2023 is as follows (in thousands): 2023 2024 2025 2026 2027 2028 and thereafter Total Amortization expense $ 495 $ 990 $ 810 $ 524 $ 471 $ 2,652 $ 5,942

Debt

Debt	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Debt	Debt On February 5, 2021 , the Company entered into a Credit Agreement (the “ 2021 Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”), sole bookrunner and sole lead arranger, and the lenders party thereto. The borrowers under the 2021 Credit Agreement are the Company, InfuSystem Holdings USA, Inc. (“Holdings”), InfuSystem, Inc. (“ISI”), First Biomedical, Inc. (“First Biomedical”), and IFC LLC (“IFC” and, collectively with the Company, Holdings, ISI and First Biomedical, the “Borrowers”). The 2021 Credit Agreement provides for a revolving credit facility (the “Revolving Facility”) of $75.0 million, that matures on February 5, 2026. The Revolving Facility may be increased by $25.0 million, subject to certain conditions, including the consent of the Agent and obtaining necessary commitments. The lenders under the 2021 Credit Agreement may issue up to $7.0 million in letters of credit subject to the satisfaction of certain conditions. On February 5, 2021, the Borrowers made an initial borrowing of $30.0 million under the Revolving Facility. Proceeds from the loan, along with approximately $8.2 million in cash, were used to repay all amounts due under the Company’s then existing credit facility dated March 23, 2015 (the “2015 Credit Agreement”). The 2021 Credit Agreement has customary representations and warranties. The ability to borrow under the facility is subject to ongoing compliance with a number of customary affirmative and negative covenants, including limitations on indebtedness, liens, mergers, acquisitions, investments, asset sales, affiliate transactions and restricted payments, as well as financial covenants, including the following: • a minimum fixed charge coverage ratio (defined as the ratio of consolidated EBITDA (as defined in the 2021 Credit Agreement) less 50% of depreciation expense), to consolidated fixed charges (as defined in the 2021 Credit Agreement)) for the prior four most recently ended calendar quarters of 1.20 to 1.00; and • a maximum leverage ratio (defined as total indebtedness to EBITDA for the prior four most recently ended calendar quarters) of 3.50 to 1.00. The 2021 Credit Agreement includes customary events of default. The occurrence of an event of default will permit the lenders to terminate commitments to lend under the Revolving Facility and accelerate payment of all amounts outstanding thereunder. Simultaneous with the execution of the 2021 Credit Agreement, the Company entered into a Pledge and Security Agreement to secure repayment of the obligations of the Borrowers. Under the Pledge and Security Agreement, each Borrower has granted to the Agent, for the benefit of various secured parties, a first priority security interest in substantially all of the personal property assets of each of the Borrowers, including the shares of each of Holdings, ISI and First Biomedical and the equity interests of IFC. On April 26, 2023, the Company entered into a First Amendment to the 2021 Credit Agreement (the "First Amendment") with the Agent and the lenders party thereto, which amended the 2021 Credit Agreement, to provide for, among other things: (i) an extension of the maturity date for the 2021 Credit Agreement to April 26, 2028, (ii) the replacement of London Interbank Offered Rate ("LIBOR") with Adjusted Term Secured Overnight Financing Rate ("SOFR") as a benchmark interest rate, and (iii) an increase of the maximum dollar amount of incremental revolving loans from $25 million to $35 million. Incremental revolving loans continue to be subject to certain conditions, including the consent of the Agent and obtaining necessary commitments. The 2021 Credit Agreement and First Amendment were accounted for as debt modifications. As of June 30, 2023, the Company was in compliance with all debt-related covenants under the 2021 Credit Agreement, as amended. The following table illustrates the net availability under the Revolving Facility as of the applicable balance sheet date (in thousands): June 30, December 31, Revolving Facility: Gross availability $ 75,000 $ 75,000 Outstanding draws (36,517) (33,384) Letter of credit (400) (400) Availability on Revolving Facility $ 38,083 $ 41,216 The Company had future maturities of its long-term debt as of June 30, 2023 as follows (in thousands): 2023 2024 2025 2026 2027 and thereafter Total Revolving Facility $ — $ — $ — $ — $ 36,517 $ 36,517 Total $ — $ — $ — $ — $ 36,517 $ 36,517 The following is a breakdown of the Company’s current and long-term debt (in thousands): June 30, 2023 December 31, 2022 Current Portion Long-Term Portion Total Current Portion Long-Term Portion Total Revolving Facility $ — $ 36,517 $ 36,517 $ — $ 33,384 $ 33,384 Unamortized value of debt issuance costs — (377) (377) — (227) (227) Total $ — $ 36,140 $ 36,140 $ — $ 33,157 $ 33,157 As of June 30, 2023, amounts outstanding under the Revolving Facility provided under the 2021 Credit Agreement, as amended, bear interest at a variable rate equal to, at the Company’s election, Adjusted Term SOFR for Term Benchmark loans or an Alternative Base Rate for ABR loans, as defined by the First Amendment , plus a spread that will vary depending upon the Company’s leverage ratio. The spread ranges from 2.00% to 3.00% for Term Benchmark Loans and 1.00% to 2.00% for base rate loans. The weighted-average Term Benchmark loan rate at June 30, 2023 was 7.47% (Adjusted Term SOFR of 5.22% plus 2.25%). The actual ABR loan rate at June 30, 2023 was 9.50% (lender’s prime rate of 8.25% plus 1.25%).

Derivative Financial Instrument

Derivative Financial Instruments and Hedging Activities	6 Months Ended
	Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments and Hedging Activities	Derivative Financial Instruments and Hedging Activities In February 2021, the Company adopted a derivative investment policy, which provides guidelines and objectives related to managing financial and operational exposures arising from market changes in short term interest rates. In accordance with this policy, the Company can enter into interest rate swaps or similar instruments, will endeavor to evaluate all the risks inherent in a transaction before entering into a derivative financial instrument and will not enter into derivative financial instruments for speculative or trading purposes. Hedging relationships are formally documented at the inception of the hedge and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. The Company is exposed to interest rate risk related to its variable rate debt obligations under the 2021 Credit Agreement. In order to manage the volatility in interest rate markets, in February 2021, the Company entered into two interest rate swap agreements to manage exposure arising from this risk. On a combined basis, the agreements had a constant notional amount over a five-year term that would have ended on February 5, 2026. While they were outstanding, each agreement paid the Company 30-day LIBOR on the notional amount and the Company paid a fixed rate of interest equal to 0.73%. These derivative instruments were considered cash flow hedges. On May 11, 2023, these two swaps were settled and a new swap was entered into with different terms that aligned with changes in the 2021 Credit Agreement arising from the First Amendment. The new swap has a constant notional amount over a five-year term that ends on April 26, 2028. The agreement pays the Company 30-day SOFR on the notional amount and the Company pays a fixed rate of interest equal to 1.74%. The Company does not have any other derivative financial instruments. The fair values of the Company’s derivative financial instruments are categorized as Level II of the fair value hierarchy as the values are derived using the market approach based on observable market inputs including quoted prices of similar instruments and interest rate forward curves. The tables below present the location and gross fair value amounts of the Company's derivative financial instruments and the associated notional amounts designated as cash flow hedges as of the applicable balance sheet date (in thousands): June 30, 2023 Balance Sheet Location Notional Fair Value Derivative Assets Derivatives designated as hedges: Cash flow hedges Interest rate swaps Derivative financial instruments $ 20,000 $ 1,910 December 31, 2022 Balance Sheet Location Notional Fair Value Derivative Assets Derivatives designated as hedges: Cash flow hedges Interest rate swaps Derivative financial instruments $ 20,000 $ 1,965 The table below presents the effect of our derivative financial instruments designated as hedging instruments in AOCI (in thousands): Three Months Ended June 30, 2023 2022 Gain on cash flow hedges - interest rate swaps Beginning balance $ 1,270 $ 955 Unrealized gain recognized in AOCI 412 246 Amounts reclassified to interest expense (a) (184) (2) Tax provision (56) (59) Ending balance $ 1,442 $ 1,140 (a) Negative amounts represent interest income. Interest expense as presented in the condensed consolidated statement of operations and comprehensive income for the three months ended June 30, 2023 and 2022 was $0.6 million and $0.3 million, respectively. Six Months Ended June 30, 2023 2022 Gain on cash flow hedges - interest rate swaps Beginning balance $ 1,489 $ 268 Unrealized gain recognized in AOCI 320 1123 Amounts reclassified to interest expense (a) (b) (374) 26 Tax provision 7 (277) Ending balance $ 1,442 $ 1140 (a) Negative amounts represent interest income and positive amounts represent interest expense. Interest expense as presented in the condensed consolidated statement of operations and comprehensive income for the six months ended June 30, 2023 and 2022 was $1.1 million and $0.6 million, respectively. (b) As of June 30, 2023, $0.7 million of income is expected to be reclassified into earnings within the next 12 months. The Company did not incur any hedge ineffectiveness during the six months ended June 30, 2023.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesDuring the three and six months ended June 30, 2023, the Company recorded a provision for income taxes of $0.2 million and a benefit from income taxes of $0.1 million, respectively. The income tax benefit for the six months ended June 30, 2023 relates principally to the Company's low pre-tax income during the period and also includes a benefit from excess tax benefits on exercises of stock options and vesting of restricted stock during the period. For the three and six months ended June 30, 2022, the Company recorded a provision for income taxes of less than $0.1 million and a benefit from income taxes of $0.4 million, respectively.

Commitments, Contingencies and

Commitments, Contingencies and Litigation	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Litigation	Commitments, Contingencies and Litigation From time to time in the ordinary course of its business, the Company may be involved in legal and regulatory proceedings, the outcomes of which may not be determinable. The results of litigation and regulatory proceedings are inherently unpredictable. Any claims against the Company, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. The Company is not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages and, until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. The Company has insurance policies covering potential losses where such coverage is cost effective. The Company is not at this time involved in any proceedings that the Company currently believes could have a material effect on the Company’s financial condition, results of operations or cash flows.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	Earnings (Loss) Per ShareBasic income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share assumes the issuance of potentially dilutive shares of common stock during the period. The following table reconciles the numerators and denominators of the basic and diluted income (loss) per share computations: Three Months Ended June 30, Six Months Ended June 30, Numerator (in thousands) : 2023 2022 2023 2022 Net income (loss): $ 435 $ (164) $ 111 $ (532) Denominator: Weighted average common shares outstanding: Basic 20,955,048 20,583,928 20,904,315 20,596,580 Dilutive effect of common stock equivalents 645,298 — 661,352 — Diluted 21,600,346 20,583,928 21,565,667 20,596,580 Net income (loss) per share: Basic $ 0.02 $ (0.01) $ 0.01 $ (0.03) Diluted $ 0.02 $ (0.01) $ 0.01 $ (0.03) For the three and six months ended June 30, 2023, there were 901,995 and 755,234, respectively, of outstanding options and unvested restricted stock units with an exercise price above the current market value of the Company's common stock that were not included in the calculation because they would have an anti-dilutive effect. For both the three and six months ended June 30, 2022, all outstanding options and unvested restricted stock units were anti-dilutive due to the Company's net losses for the periods and therefore not included in the calculation. Share Repurchase Program On June 30, 2021, our Board of Directors approved a stock repurchase program (the “Share Repurchase Program”) that authorizes the Company to repurchase up to $20.0 million of the Company’s outstanding common stock through June 30, 2024. Repurchases under the Share Repurchase Program are subject to market conditions, the periodic capital needs of the Company’s operating activities, and the continued satisfaction of all covenants under the Company’s existing 2021 Credit Agreement, as amended. Repurchases under the Share Repurchase Program may take place in the open market or in privately negotiated transactions and may be made under a Rule 10b5-1 plan. The Share Repurchase Program does not obligate the Company to repurchase shares and may be suspended, terminated, or modified at any time at the discretion of the Board. As of June 30, 2023, the Company had repurchased and retired approximately $6.2 million, or 553,149 shares, of the Company's outstanding common stock under the Share Repurchase Program.

Leases

Leases	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Leases	Leases The Company’s operating leases are primarily for office space, service facility centers and equipment under operating lease arrangements that expire at various dates over the next eight years. The Company’s leases do not contain any restrictive covenants. The Company’s office leases generally contain renewal options for periods ranging from one Payments due under the Company’s operating leases include fixed payments as well as variable payments. For the Company’s office leases, variable payments include amounts for the Company’s proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For the Company’s equipment leases, variable payments may consist of sales taxes, property taxes and other fees. The components of lease costs for the three and six months ended June 30, 2023 and 2022 are as follows (in thousands): Three Months Ended Six Months Ended 2023 2022 2023 2022 Operating lease cost $ 369 $ 335 $ 721 $ 664 Variable lease cost 87 80 163 154 Total lease cost $ 456 $ 415 $ 884 $ 818 Supplemental cash flow information and non-cash activity related to the Company’s leases are as follows (in thousands): Six Months Ended 2023 2022 Cash paid for amounts included in the measurement of lease liabilities and right of use assets: Operating cash flow from operating leases $ 773 $ 523 Right of use assets obtained in exchange for lease obligations: Operating leases $ 406 $ 18 Increases to right of use assets resulting from lease modifications: Operating leases $ 552 $ 1,050 Weighted average remaining lease terms and discount rates for the Company’s operating leases are as follows: As of June 30, 2023 2022 Years Years Weighted average remaining lease term: 5.6 7.1 Rate Rate Weighted average discount rate: 6.9% 7.1% Future maturities of lease liabilities as of June 30, 2023 are as follows (in thousands): Operating Leases (a) 2023 $ 665 2024 1,337 2025 1,267 2026 1,096 2027 910 2028 and thereafter 2,015 Total undiscounted lease payments 7,290 Less: Imputed interest (2,359) Total lease liabilities $ 4,931 (a) Excludes $1.8 million of legally binding minimum lease payments for an office lease signed but not yet commenced. This lease has an expected term of 7 years and is expected to commence in the fourth quarter of 2023.

Business Segment Information

Business Segment Information	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Business Segment Information	Business Segment InformationDuring the second quarter of 2023, the Company renamed its two operating segments. Prior to that time the Patient Services segment was known as Integrated Therapy Services and the Device Solutions segment was known as Durable Medical Equipment Services. The changes were for marketing purposes only and there were no changes to the operations of either segment. The Company’s reportable segments are organized based on service platforms, with the Patient Services segment reflecting higher margin rental revenues that generally include payments made by third-party and direct payers and the Device Solutions segment reflecting lower margin product sales, direct payer rental and service revenues. Resources are allocated and performance is assessed for these segments by the Company’s Chief Executive Officer, whom the Company has determined to be its chief operating decision-maker. The Company believes that reporting performance at the gross profit level is the best indicator of segment performance. The financial information summarized below is presented by reportable segment for the three months ended June 30, 2023 and 2022: 2023 (in thousands) Patient Services Device Solutions Corporate/ Eliminations Total Net revenues - external $ 19,319 $ 12,416 $ — $ 31,735 Net revenues - internal — 1,681 (1,681) — Total net revenues 19,319 14,097 (1,681) 31,735 Gross profit 11,845 4,597 — 16,442 Selling, general and administrative expenses 15,194 15,194 Interest expense (620) (620) Other income 2 2 Provision for income taxes (195) (195) Net income $ 435 Total assets $ 60,243 $ 40,506 $ 2,000 $ 102,749 Purchases of medical equipment $ 1,539 $ 1,487 $ — $ 3,026 Depreciation and amortization of intangible assets $ 2,078 $ 1,015 $ — $ 3,093 2022 (in thousands) Patient Services Device Solutions Corporate/ Eliminations Total Net revenues - external $ 17,244 $ 9,798 $ — $ 27,042 Net revenues - internal — 1,762 (1,762) — Total net revenues 17,244 11,560 (1,762) 27,042 Gross profit 10,113 4,788 — 14,901 Selling, general and administrative expenses 14,694 14,694 Interest expense (314) (314) Other expense (30) (30) Provision for income taxes (27) (27) Net loss $ (164) Total assets $ 62,310 $ 34,507 $ 2,000 $ 98,817 Purchases of medical equipment $ 3,325 $ 413 $ — $ 3,738 Depreciation and amortization of intangible assets $ 2,371 $ 1,029 $ — $ 3,400 The financial information summarized below is presented by reportable segment for the six months ended June 30, 2023 and 2022: 2023 (in thousands) Patient Services Device Solutions Corporate/ Eliminations Total Net revenues - external $ 38,093 $ 24,012 $ — $ 62,105 Net revenues - internal — 3,311 (3,311) — Total net revenues 38,093 27,323 (3,311) 62,105 Gross profit 23,386 8,596 — 31,982 Selling, general and administrative expenses 30,841 30,841 Interest expense (1,104) (1,104) Other expense (33) (33) Benefit from income taxes 107 107 Net income $ 111 Total assets $ 60,243 $ 40,506 $ 2,000 $ 102,749 Purchases of medical equipment $ 4,212 $ 2,782 $ — $ 6,994 Depreciation and amortization of intangible assets $ 4,256 $ 2,040 $ — $ 6,296 2022 (in thousands) Patient Services Device Solutions Corporate/ Eliminations Total Net revenues - external $ 33,885 $ 19,920 $ — $ 53,805 Net revenues - internal — 3,250 (3,250) — Total net revenues 33,885 23,170 (3,250) 53,805 Gross profit 20,851 9,417 — 30,268 Selling, general and administrative expenses 30,586 30,586 Interest expense (591) (591) Other expense (58) (58) Benefit from income taxes 435 435 Net loss $ (532) Total assets $ 62,310 $ 34,507 $ 2,000 $ 98,817 Purchases of medical equipment $ 4,836 $ 1,833 $ — $ 6,669 Depreciation and amortization of intangible assets $ 4,769 $ 2,047 $ — $ 6,816

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Schedule of the Company’s Disaggregated Revenue	The following tables present the Company’s disaggregated revenue by offering type (in thousands): Three Months Ended 2023 2022 Total Net Revenues Percentage of Total Net Revenues Total Net Revenues Percentage of Total Net Revenues Patient Services Third-Party Payer Rentals $ 14,634 46.1 % $ 13,896 51.4 % Device Solutions Direct Payer Rentals 4,591 14.4 % 4,640 17.1 % Patient Services Direct Payer Rentals 3,356 10.6 % 3,342 12.4 % Device Solutions Product Sales 3,864 12.2 % 3,655 13.5 % Device Solutions - Service 3,961 12.5 % 1,502 5.6 % Patient Services Product Sales 1,329 4.2 % 7 — % Total $ 31,735 100.0 % $ 27,042 100.0 % Six Months Ended 2023 2022 Total Net Revenues Percentage of Total Net Revenues Total Net Revenues Percentage of Total Net Revenues Patient Services Third-Party Payer Rentals $ 29,442 47.4 % $ 27,264 50.7 % Device Solutions Direct Payer Rentals 9,098 14.7 % 9,415 17.5 % Patient Services Direct Payer Rentals 6,828 11.0 % 6,529 12.1 % Device Solutions Product Sales 7,603 12.2 % 7,313 13.6 % Device Solutions - Service 7,311 11.8 % 3,191 5.9 % Patient Services Product Sales 1,823 2.9 % 93 0.2 % Total $ 62,105 100.0 % $ 53,805 100.0 %

Medical Equipment (Tables)

Medical Equipment (Tables)	6 Months Ended
	Jun. 30, 2023
Medical Equipment [Abstract]
Schedule of Medical Equipment	Medical equipment consisted of the following (in thousands): June 30, December 31, 2022 Medical equipment for sale or rental $ 3,239 $ 2,802 Medical equipment for sale or rental - pump reserve (33) (12) Medical equipment for sale or rental - net 3,206 2,790 Medical equipment in rental service 101,165 99,163 Medical equipment in rental service - pump reserve (2,699) (2,270) Accumulated depreciation (60,769) (57,443) Medical equipment in rental service - net 37,697 39,450 Total $ 40,903 $ 42,240

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property and equipment consisted of the following (in thousands): June 30, 2023 December 31, 2022 Gross Assets Accumulated Depreciation Total Gross Assets Accumulated Depreciation Total Furniture, fixtures, and equipment $ 6,162 $ (3,600) $ 2,562 $ 5,710 $ (3,252) $ 2,458 Automobiles 87 (85) 2 87 (83) 4 Leasehold improvements 3,498 (1,759) 1,739 3,498 (1,575) 1,923 Total $ 9,747 $ (5,444) $ 4,303 $ 9,295 $ (4,910) $ 4,385

Goodwill & Intangible Assets (T

Goodwill & Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the carrying value of goodwill by segment for the six months ended June 30, 2023 are as follows (in thousands): Device Solutions (a) Balance as of December 31, 2022 $ 3,710 Goodwill acquired — Balance as of June 30, 2023 $ 3,710 (a) The Patient Services segment had no recorded goodwill during the reported periods.
Schedule of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets	The carrying amount and accumulated amortization of intangible assets consisted of the following (in thousands): June 30, 2023 December 31, 2022 Gross Assets Accumulated Amortization Net Gross Assets Accumulated Amortization Net Nonamortizable intangible assets Trade names $ 2,000 $ — $ 2,000 $ 2,000 $ — $ 2,000 Amortizable intangible assets: Trade names 23 (23) — 23 (23) — Physician and customer relationships 38,834 (33,944) 4,890 38,834 (33,594) 5,240 Non-competition agreements 472 (208) 264 472 (161) 311 Unpatented technology 943 (325) 618 943 (258) 685 Software 10,300 (10,130) 170 10,300 (10,100) 200 Total nonamortizable and amortizable intangible assets $ 52,572 $ (44,630) $ 7,942 $ 52,572 $ (44,136) $ 8,436
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Expected remaining annual amortization expense for the next five years for intangible assets recorded as of June 30, 2023 is as follows (in thousands): 2023 2024 2025 2026 2027 2028 and thereafter Total Amortization expense $ 495 $ 990 $ 810 $ 524 $ 471 $ 2,652 $ 5,942

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Schedule of Line of Credit Facilities	The following table illustrates the net availability under the Revolving Facility as of the applicable balance sheet date (in thousands): June 30, December 31, Revolving Facility: Gross availability $ 75,000 $ 75,000 Outstanding draws (36,517) (33,384) Letter of credit (400) (400) Availability on Revolving Facility $ 38,083 $ 41,216
Schedule of Maturities of Long-term Debt	The Company had future maturities of its long-term debt as of June 30, 2023 as follows (in thousands): 2023 2024 2025 2026 2027 and thereafter Total Revolving Facility $ — $ — $ — $ — $ 36,517 $ 36,517 Total $ — $ — $ — $ — $ 36,517 $ 36,517
Schedule of Debt	The following is a breakdown of the Company’s current and long-term debt (in thousands): June 30, 2023 December 31, 2022 Current Portion Long-Term Portion Total Current Portion Long-Term Portion Total Revolving Facility $ — $ 36,517 $ 36,517 $ — $ 33,384 $ 33,384 Unamortized value of debt issuance costs — (377) (377) — (227) (227) Total $ — $ 36,140 $ 36,140 $ — $ 33,157 $ 33,157

Derivative Financial Instrume_2

Derivative Financial Instruments and Hedging Activities (Tables)	6 Months Ended
	Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The tables below present the location and gross fair value amounts of the Company's derivative financial instruments and the associated notional amounts designated as cash flow hedges as of the applicable balance sheet date (in thousands): June 30, 2023 Balance Sheet Location Notional Fair Value Derivative Assets Derivatives designated as hedges: Cash flow hedges Interest rate swaps Derivative financial instruments $ 20,000 $ 1,910 December 31, 2022 Balance Sheet Location Notional Fair Value Derivative Assets Derivatives designated as hedges: Cash flow hedges Interest rate swaps Derivative financial instruments $ 20,000 $ 1,965
Schedule of Derivative Instruments, Effect on AOCI	The table below presents the effect of our derivative financial instruments designated as hedging instruments in AOCI (in thousands): Three Months Ended June 30, 2023 2022 Gain on cash flow hedges - interest rate swaps Beginning balance $ 1,270 $ 955 Unrealized gain recognized in AOCI 412 246 Amounts reclassified to interest expense (a) (184) (2) Tax provision (56) (59) Ending balance $ 1,442 $ 1,140 (a) Negative amounts represent interest income. Interest expense as presented in the condensed consolidated statement of operations and comprehensive income for the three months ended June 30, 2023 and 2022 was $0.6 million and $0.3 million, respectively. Six Months Ended June 30, 2023 2022 Gain on cash flow hedges - interest rate swaps Beginning balance $ 1,489 $ 268 Unrealized gain recognized in AOCI 320 1123 Amounts reclassified to interest expense (a) (b) (374) 26 Tax provision 7 (277) Ending balance $ 1,442 $ 1140 (a) Negative amounts represent interest income and positive amounts represent interest expense. Interest expense as presented in the condensed consolidated statement of operations and comprehensive income for the six months ended June 30, 2023 and 2022 was $1.1 million and $0.6 million, respectively. (b) As of June 30, 2023, $0.7 million of income is expected to be reclassified into earnings within the next 12 months.

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table reconciles the numerators and denominators of the basic and diluted income (loss) per share computations: Three Months Ended June 30, Six Months Ended June 30, Numerator (in thousands) : 2023 2022 2023 2022 Net income (loss): $ 435 $ (164) $ 111 $ (532) Denominator: Weighted average common shares outstanding: Basic 20,955,048 20,583,928 20,904,315 20,596,580 Dilutive effect of common stock equivalents 645,298 — 661,352 — Diluted 21,600,346 20,583,928 21,565,667 20,596,580 Net income (loss) per share: Basic $ 0.02 $ (0.01) $ 0.01 $ (0.03) Diluted $ 0.02 $ (0.01) $ 0.01 $ (0.03)

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Schedule of the Components of Lease Costs	The components of lease costs for the three and six months ended June 30, 2023 and 2022 are as follows (in thousands): Three Months Ended Six Months Ended 2023 2022 2023 2022 Operating lease cost $ 369 $ 335 $ 721 $ 664 Variable lease cost 87 80 163 154 Total lease cost $ 456 $ 415 $ 884 $ 818 Supplemental cash flow information and non-cash activity related to the Company’s leases are as follows (in thousands): Six Months Ended 2023 2022 Cash paid for amounts included in the measurement of lease liabilities and right of use assets: Operating cash flow from operating leases $ 773 $ 523 Right of use assets obtained in exchange for lease obligations: Operating leases $ 406 $ 18 Increases to right of use assets resulting from lease modifications: Operating leases $ 552 $ 1,050 Weighted average remaining lease terms and discount rates for the Company’s operating leases are as follows: As of June 30, 2023 2022 Years Years Weighted average remaining lease term: 5.6 7.1 Rate Rate Weighted average discount rate: 6.9% 7.1%
Schedule of Future Maturities of Lease Liabilities	Future maturities of lease liabilities as of June 30, 2023 are as follows (in thousands): Operating Leases (a) 2023 $ 665 2024 1,337 2025 1,267 2026 1,096 2027 910 2028 and thereafter 2,015 Total undiscounted lease payments 7,290 Less: Imputed interest (2,359) Total lease liabilities $ 4,931 (a) Excludes $1.8 million of legally binding minimum lease payments for an office lease signed but not yet commenced. This lease has an expected term of 7 years and is expected to commence in the fourth quarter of 2023.

Business Segment Information (T

Business Segment Information (Tables)	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The financial information summarized below is presented by reportable segment for the three months ended June 30, 2023 and 2022: 2023 (in thousands) Patient Services Device Solutions Corporate/ Eliminations Total Net revenues - external $ 19,319 $ 12,416 $ — $ 31,735 Net revenues - internal — 1,681 (1,681) — Total net revenues 19,319 14,097 (1,681) 31,735 Gross profit 11,845 4,597 — 16,442 Selling, general and administrative expenses 15,194 15,194 Interest expense (620) (620) Other income 2 2 Provision for income taxes (195) (195) Net income $ 435 Total assets $ 60,243 $ 40,506 $ 2,000 $ 102,749 Purchases of medical equipment $ 1,539 $ 1,487 $ — $ 3,026 Depreciation and amortization of intangible assets $ 2,078 $ 1,015 $ — $ 3,093 2022 (in thousands) Patient Services Device Solutions Corporate/ Eliminations Total Net revenues - external $ 17,244 $ 9,798 $ — $ 27,042 Net revenues - internal — 1,762 (1,762) — Total net revenues 17,244 11,560 (1,762) 27,042 Gross profit 10,113 4,788 — 14,901 Selling, general and administrative expenses 14,694 14,694 Interest expense (314) (314) Other expense (30) (30) Provision for income taxes (27) (27) Net loss $ (164) Total assets $ 62,310 $ 34,507 $ 2,000 $ 98,817 Purchases of medical equipment $ 3,325 $ 413 $ — $ 3,738 Depreciation and amortization of intangible assets $ 2,371 $ 1,029 $ — $ 3,400 The financial information summarized below is presented by reportable segment for the six months ended June 30, 2023 and 2022: 2023 (in thousands) Patient Services Device Solutions Corporate/ Eliminations Total Net revenues - external $ 38,093 $ 24,012 $ — $ 62,105 Net revenues - internal — 3,311 (3,311) — Total net revenues 38,093 27,323 (3,311) 62,105 Gross profit 23,386 8,596 — 31,982 Selling, general and administrative expenses 30,841 30,841 Interest expense (1,104) (1,104) Other expense (33) (33) Benefit from income taxes 107 107 Net income $ 111 Total assets $ 60,243 $ 40,506 $ 2,000 $ 102,749 Purchases of medical equipment $ 4,212 $ 2,782 $ — $ 6,994 Depreciation and amortization of intangible assets $ 4,256 $ 2,040 $ — $ 6,296 2022 (in thousands) Patient Services Device Solutions Corporate/ Eliminations Total Net revenues - external $ 33,885 $ 19,920 $ — $ 53,805 Net revenues - internal — 3,250 (3,250) — Total net revenues 33,885 23,170 (3,250) 53,805 Gross profit 20,851 9,417 — 30,268 Selling, general and administrative expenses 30,586 30,586 Interest expense (591) (591) Other expense (58) (58) Benefit from income taxes 435 435 Net loss $ (532) Total assets $ 62,310 $ 34,507 $ 2,000 $ 98,817 Purchases of medical equipment $ 4,836 $ 1,833 $ — $ 6,669 Depreciation and amortization of intangible assets $ 4,769 $ 2,047 $ — $ 6,816

Basis of Presentation, Nature_2

Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies (Details)	6 Months Ended
	Jun. 30, 2023 segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable segments	2
Number of operating segments	2

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregated Revenue by Revenue Stream (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation of Revenue [Line Items]
Total Net Revenues	$ 31,735	$ 27,042	$ 62,105	$ 53,805
Third-Party Payer Rentals | Patient Services
Disaggregation of Revenue [Line Items]
Total Net Revenues	14,634	13,896	29,442	27,264
Direct Payer Rentals | Patient Services
Disaggregation of Revenue [Line Items]
Total Net Revenues	3,356	3,342	6,828	6,529
Direct Payer Rentals | Device Solutions
Disaggregation of Revenue [Line Items]
Total Net Revenues	4,591	4,640	9,098	9,415
Product Sales | Patient Services
Disaggregation of Revenue [Line Items]
Total Net Revenues	1,329	7	1,823	93
Product Sales | Device Solutions
Disaggregation of Revenue [Line Items]
Total Net Revenues	3,864	3,655	7,603	7,313
Service | Device Solutions
Disaggregation of Revenue [Line Items]
Total Net Revenues	$ 3,961	$ 1,502	$ 7,311	$ 3,191
Revenue from Contract with Customer Benchmark | Customer Concentration Risk
Disaggregation of Revenue [Line Items]
Percentage of Total Net Revenues	100%	100%	100%	100%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Third-Party Payer Rentals | Patient Services
Disaggregation of Revenue [Line Items]
Percentage of Total Net Revenues	46.10%	51.40%	47.40%	50.70%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Direct Payer Rentals | Patient Services
Disaggregation of Revenue [Line Items]
Percentage of Total Net Revenues	10.60%	12.40%	11%	12.10%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Direct Payer Rentals | Device Solutions
Disaggregation of Revenue [Line Items]
Percentage of Total Net Revenues	14.40%	17.10%	14.70%	17.50%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Product Sales | Patient Services
Disaggregation of Revenue [Line Items]
Percentage of Total Net Revenues	4.20%	0%	2.90%	0.20%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Product Sales | Device Solutions
Disaggregation of Revenue [Line Items]
Percentage of Total Net Revenues	12.20%	13.50%	12.20%	13.60%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Service | Device Solutions
Disaggregation of Revenue [Line Items]
Percentage of Total Net Revenues	12.50%	5.60%	11.80%	5.90%

Medical Equipment - Summary of

Medical Equipment - Summary of Medical Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Medical Equipment [Abstract]
Medical equipment for sale or rental	$ 3,239	$ 2,802
Medical equipment for sale or rental - pump reserve	(33)	(12)
Medical equipment for sale or rental - net	3,206	2,790
Medical equipment in rental service	101,165	99,163
Medical equipment in rental service - pump reserve	(2,699)	(2,270)
Accumulated depreciation	(60,769)	(57,443)
Medical equipment in rental service - net	37,697	39,450
Total	$ 40,903	$ 42,240

Medical Equipment - Narrative (

Medical Equipment - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Medical Equipment [Abstract]
Depreciation expense related to medical equipment	$ 2.6	$ 2.5	$ 5.3	$ 4.9

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Gross Assets	$ 9,747	$ 9,295
Accumulated Depreciation	(5,444)	(4,910)
Total	4,303	4,385
Furniture, fixtures, and equipment
Property, Plant and Equipment [Line Items]
Gross Assets	6,162	5,710
Accumulated Depreciation	(3,600)	(3,252)
Total	2,562	2,458
Automobiles
Property, Plant and Equipment [Line Items]
Gross Assets	87	87
Accumulated Depreciation	(85)	(83)
Total	2	4
Leasehold improvements
Property, Plant and Equipment [Line Items]
Gross Assets	3,498	3,498
Accumulated Depreciation	(1,759)	(1,575)
Total	$ 1,739	$ 1,923

Property and Equipment - Narrat

Property and Equipment - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation	$ 0.2	$ 0.5	$ 0.2	$ 0.5

Goodwill & Intangible Assets -

Goodwill & Intangible Assets - Goodwill (Details)	6 Months Ended
	Jun. 30, 2023 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 3,710,000
Goodwill, ending balance	3,710,000
Device Solutions
Goodwill [Roll Forward]
Goodwill, beginning balance	3,710,000
Goodwill acquired	0
Goodwill, ending balance	3,710,000
Patient Services
Goodwill [Roll Forward]
Goodwill, ending balance	$ 0

Goodwill & Intangible Assets _2

Goodwill & Intangible Assets - Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Goodwill [Line Items]
Trade names	$ 2,000	$ 2,000
Accumulated Amortization	(44,630)	(44,136)
Total	5,942
Total nonamortizable and amortizable intangible assets	52,572	52,572
Net	7,942	8,436
Trade names
Goodwill [Line Items]
Gross Assets	23	23
Accumulated Amortization	(23)	(23)
Total	0	0
Physician and customer relationships
Goodwill [Line Items]
Gross Assets	38,834	38,834
Accumulated Amortization	(33,944)	(33,594)
Total	4,890	5,240
Non-competition agreements
Goodwill [Line Items]
Gross Assets	472	472
Accumulated Amortization	(208)	(161)
Total	264	311
Unpatented technology
Goodwill [Line Items]
Gross Assets	943	943
Accumulated Amortization	(325)	(258)
Total	618	685
Software
Goodwill [Line Items]
Gross Assets	10,300	10,300
Accumulated Amortization	(10,130)	(10,100)
Total	$ 170	$ 200

Goodwill & Intangible Assets _3

Goodwill & Intangible Assets - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 247	$ 711	$ 495	$ 1,421

Goodwill & Intangible Assets _4

Goodwill & Intangible Assets - Expected Annual Amortization Expense for Intangible Assets (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 495
2024	990
2025	810
2026	524
2027	471
2028 and thereafter	2,652
Total	$ 5,942

Debt - Narrative (Details)

Debt - Narrative (Details) $ in Millions		6 Months Ended
	Feb. 05, 2021 USD ($)	Jun. 30, 2023	Apr. 26, 2023 USD ($)	Apr. 25, 2023 USD ($)
The 2021 Credit Agreement
Debt Instrument [Line Items]
Percentage of total depreciation expense	50%
Debt instrument, covenant, minimum fixed coverage ratio	1.20
Debt instrument, covenant, maximum leverage ratio	3.50
The 2021 Credit Agreement | Term Benchmark Loans
Debt Instrument [Line Items]
Effective percentage		7.47%
LIBOR rate		5.22%
The 2021 Credit Agreement | ABR Loans
Debt Instrument [Line Items]
Effective percentage		9.50%
The 2021 Credit Agreement | Secured Overnight Financing Rate (SOFR) | Term Benchmark Loans
Debt Instrument [Line Items]
Basis spread on variable rate		2.25%
The 2021 Credit Agreement | Base Rate | ABR Loans
Debt Instrument [Line Items]
Basis spread on variable rate		1.25%
The 2021 Credit Agreement | Minimum | Secured Overnight Financing Rate (SOFR) | Term Benchmark Loans
Debt Instrument [Line Items]
Basis spread on variable rate		2%
The 2021 Credit Agreement | Minimum | Base Rate | ABR Loans
Debt Instrument [Line Items]
Basis spread on variable rate		1%
Lender prime rate		8.25%
The 2021 Credit Agreement | Maximum | Secured Overnight Financing Rate (SOFR) | Term Benchmark Loans
Debt Instrument [Line Items]
Basis spread on variable rate		3%
The 2021 Credit Agreement | Maximum | Base Rate | ABR Loans
Debt Instrument [Line Items]
Basis spread on variable rate		2%
The 2021 Credit Agreement | Revolving Facility
Debt Instrument [Line Items]
Line of credit facility	$ 75
Revolving credit facility	25		$ 35	$ 25
Borrowings under revolving credit facility	30
The 2021 Credit Agreement | Letter of credit
Debt Instrument [Line Items]
Line of credit facility	7
The 2015 Credit Agreement | Revolving Facility
Debt Instrument [Line Items]
Repayments	$ 8.2

Debt - Summary of Revolver Base

Debt - Summary of Revolver Based Upon Borrowers' Eligible Accounts Receivable and Inventory (Details) - Revolving Facility - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Gross availability	$ 75,000	$ 75,000
Outstanding draws	(36,517)	(33,384)
Letter of credit	(400)	(400)
Availability on Revolving Facility	$ 38,083	$ 41,216

Debt - Summary of Future Maturi

Debt - Summary of Future Maturities of Loans (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
2023	$ 0
2024	0
2025	0
2026	0
2027 and thereafter	36,517
Total	36,517
Revolving Facility
Debt Instrument [Line Items]
2023	0
2024	0
2025	0
2026	0
2027 and thereafter	36,517
Total	$ 36,517	$ 33,384

Debt - Summary of Company's Cur

Debt - Summary of Company's Current and Long-term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Total	$ 36,517
Unamortized value of the debt issuance costs, current portion of long-term debt	0	$ 0
Unamortized value of the debt issuance costs, long-term debt	(377)	(227)
Unamortized value of the debt issuance costs, total	(377)	(227)
Current portion of long-term debt	0	0
Long-term debt	36,140	33,157
Total	36,140	33,157
Revolving Facility
Debt Instrument [Line Items]
Current Portion	0	0
Long-Term Portion	36,517	33,384
Total	$ 36,517	$ 33,384

Derivative Financial Instrume_3

Derivative Financial Instruments and Hedging Activities - Narrative (Details) - Interest rate swaps - Derivatives designated as hedges: - Cash flow hedges			6 Months Ended
	May 11, 2023 agreement	Feb. 05, 2021 agreement	Jun. 30, 2023 USD ($)
Derivative [Line Items]
Interest rate swap | agreement	2	2
Term of contract (year)	5 years	5 years
Fixed interest rate	1.74%	0.73%
Net hedge effectiveness | $			$ 0

Derivative Financial Instrume_4

Derivative Financial Instruments and Hedging Activities - Fair Value and Notional Amounts of Cash Flow Hedges (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Derivative [Line Items]
Fair Value Derivative Assets	$ 1,910	$ 1,965
Cash flow hedges | Interest rate swaps | Derivatives designated as hedges:
Derivative [Line Items]
Notional	20,000	20,000
Fair Value Derivative Assets	$ 1,910	$ 1,965

Derivative Financial Instrume_5

Derivative Financial Instruments and Hedging Activities - Derivative Financial Instruments Designated as Hedging Instruments in AOCI (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Derivatives used in Net Investment Hedge, Net of Tax [Roll Forward]
Beginning balance	$ 48,261	$ 46,053	$ 48,003	$ 48,272
Ending balance	49,956	46,497	49,956	46,497
Interest expense	620	314	1,104	591
Interest rate swaps | Cash flow hedges | Derivatives designated as hedges:
Derivatives used in Net Investment Hedge, Net of Tax [Roll Forward]
Reclassified within twelve months			700
Gain/(loss) on cash flow hedges
Derivatives used in Net Investment Hedge, Net of Tax [Roll Forward]
Beginning balance	1,270	955	1,489	268
Unrealized gain recognized in AOCI	412	246	320	1,123
Amounts reclassified to interest expense	(184)	(2)	(374)	26
Tax provision	(56)	(59)	7	(277)
Ending balance	$ 1,442	$ 1,140	$ 1,442	$ 1,140

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income tax expense (benefit) (less than)	$ 195	$ 27	$ (107)	$ (435)

Earnings (Loss) Per Share - Cal

Earnings (Loss) Per Share - Calculation of Basic and Diluted EPS (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Net income (loss)	$ 435	$ (164)	$ 111	$ (532)
Weighted average common shares outstanding:
Basic (in shares)	20,955,048	20,583,928	20,904,315	20,596,580
Dilutive effect of common stock equivalents (in shares)	645,298	0	661,352	0
Diluted (in shares)	21,600,346	20,583,928	21,565,667	20,596,580
Basic (in dollars per share)	$ 0.02	$ (0.01)	$ 0.01	$ (0.03)
Diluted (in dollars per share)	$ 0.02	$ (0.01)	$ 0.01	$ (0.03)

Earnings (Loss) Per Share - Nar

Earnings (Loss) Per Share - Narrative (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2021
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	901,995	755,234
Stock repurchase program, authorized amount			$ 20,000,000
Cumulative shares purchased	$ 6,200,000	$ 6,200,000
Cumulative shares purchased (in shares)	553,149	553,149

Leases - Narrative (Details)

Leases - Narrative (Details)	Jun. 30, 2023
Lessee, Lease, Description [Line Items]
Operating lease, term of contract	8 years
Minimum | Office Leases With Renewal Options Not Reasonably Certain to Exercise
Lessee, Lease, Description [Line Items]
Lessee, operating lease, renewal term (year)	1 year
Maximum | Office Leases With Renewal Options Not Reasonably Certain to Exercise
Lessee, Lease, Description [Line Items]
Lessee, operating lease, renewal term (year)	5 years

Leases - Lease Cost (Details)

Leases - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Leases [Abstract]
Operating lease cost	$ 369	$ 335	$ 721	$ 664
Variable lease cost	87	80	163	154
Total lease cost	$ 456	$ 415	884	818
Operating cash flow from operating leases			773	523
Operating leases			406	18
Increases to right of use assets resulting from lease modifications, operating lease			$ 552	$ 1,050
Weighted average remaining lease term:	5 years 7 months 6 days	7 years 1 month 6 days	5 years 7 months 6 days	7 years 1 month 6 days
Weighted average discount rate:	6.90%	7.10%	6.90%	7.10%

Leases - Maturities of Lease Li

Leases - Maturities of Lease Liabilities (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Leases [Abstract]
2023	$ 665
2024	1,337
2025	1,267
2026	1,096
2027	910
2028 and thereafter	2,015
Total undiscounted lease payments	7,290
Less: Imputed interest	(2,359)
Total lease liabilities	4,931
Operating lease, minimum payments	$ 1,800
Lessee, finance lease, remaining lease term	7 years

Business Segment Information -

Business Segment Information - Narrative (Details)	6 Months Ended
	Jun. 30, 2023 segment
Business Combination and Asset Acquisition [Abstract]
Number of operating segments	2

Business Segment Information _2

Business Segment Information - Segment Reporting Information, by Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Segment Reporting Information [Line Items]
Net revenues - external	$ 31,735	$ 27,042	$ 62,105	$ 53,805
Net revenues - internal	0	0	0	0
Total net revenues	31,735	27,042	62,105	53,805
Gross profit	16,442	14,901	31,982	30,268
Selling, general and administrative expenses	15,194	14,694	30,841	30,586
Interest expense	(620)	(314)	(1,104)	(591)
Other income (expense)	2	(30)	(33)	(58)
Provision for income taxes	(195)	(27)	107	435
Net income (loss)	435	(164)	111	(532)
Total assets	102,749	98,817	102,749	98,817	$ 99,388
Purchases of medical equipment	3,026	3,738	6,994	6,669
Depreciation and amortization of intangible assets	3,093	3,400	6,296	6,816
Corporate and Eliminations
Segment Reporting Information [Line Items]
Net revenues - external	0	0	0	0
Net revenues - internal	(1,681)	(1,762)	(3,311)	(3,250)
Total net revenues	(1,681)	(1,762)	(3,311)	(3,250)
Gross profit	0	0	0	0
Selling, general and administrative expenses	15,194	14,694	30,841	30,586
Interest expense	(620)	(314)	(1,104)	(591)
Other income (expense)	2	(30)	(33)	(58)
Provision for income taxes	(195)	(27)	107	435
Total assets	2,000	2,000	2,000	2,000
Purchases of medical equipment	0	0	0	0
Depreciation and amortization of intangible assets	0	0	0	0
Patient Services | Operating Segments
Segment Reporting Information [Line Items]
Net revenues - external	19,319	17,244	38,093	33,885
Net revenues - internal	0	0	0	0
Total net revenues	19,319	17,244	38,093	33,885
Gross profit	11,845	10,113	23,386	20,851
Total assets	60,243	62,310	60,243	62,310
Purchases of medical equipment	1,539	3,325	4,212	4,836
Depreciation and amortization of intangible assets	2,078	2,371	4,256	4,769
Device Solutions | Operating Segments
Segment Reporting Information [Line Items]
Net revenues - external	12,416	9,798	24,012	19,920
Net revenues - internal	1,681	1,762	3,311	3,250
Total net revenues	14,097	11,560	27,323	23,170
Gross profit	4,597	4,788	8,596	9,417
Total assets	40,506	34,507	40,506	34,507
Purchases of medical equipment	1,487	413	2,782	1,833
Depreciation and amortization of intangible assets	$ 1,015	$ 1,029	$ 2,040	$ 2,047